In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer

Premila D. Leiphrakpam, Ekta Agarwal, Michelle Mathiesen, Katie L. Haferbier, Michael G. Brattain, Sanjib Chowdhury

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is the second most common cause of cancer death. The study was designed to evaluate the effects of two IGF-1R antagonists, MK-0646, a recombinant fully humanized monoclonal antibody and OSI-906, a small molecule tyrosine kinase inhibitor on CRC cells. Xenograft study was performed on IGF-1R-dependent CRC cell lines for analyzing the antitumor activity of MK-0646 and OSI-906. Tumor proliferation and apoptosis were assessed using Ki67 and TUNEL assays, respectively. We also performed in vitro characterization of MK-0646 and OSI-906 treatment on CRC cells to identify mechanisms associated with drug-induced cell death. Exposure of the GEO and CBS tumor xenografts to MK-0646 or OSI-906 led to a decrease in tumor growth. TUNEL analysis showed an increase of approximately 45-55% in apoptotic cells in both MK-0646 and OSI-906 treated tumor samples. We report the novel finding that treatment with IGF-1R antagonists led to downregulation of X-linked inhibitor of apoptosis (XIAP) protein involved in cell survival and inhibition of cell death. In conclusion, IGF-1R antagonists (MK-0646 and OSI-906) demonstrated single agent inhibition of subcutaneous CRC xenograft growth. This was coupled to pro-apoptotic effects resulting in downregulation of XIAP and inhibition of cell survival. We report a novel mechanism by which MK-0646 and OSI-906 elicits cell death in vivo and in vitro. Moreover, these results indicate that MK-0646 and OSI-906 may be potential anticancer candidates for the treatment of patients with IGF-1R-dependent CRC.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalOncology reports
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Antibodies, Monoclonal, Humanized
IGF Type 1 Receptor
Colorectal Neoplasms
Phosphotransferases
Heterografts
Cell Death
In Situ Nick-End Labeling
Neoplasms
Cell Survival
Down-Regulation
X-Linked Inhibitor of Apoptosis Protein
Apoptosis
dalotuzumab
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
Growth
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Cause of Death
Therapeutics
Cell Line

Keywords

  • Antitumor activity
  • Cell survival
  • Colorectal cancer
  • IGF-1R
  • MK-0646
  • OSI-906
  • X-linked inhibitor of apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. / Leiphrakpam, Premila D.; Agarwal, Ekta; Mathiesen, Michelle; Haferbier, Katie L.; Brattain, Michael G.; Chowdhury, Sanjib.

In: Oncology reports, Vol. 31, No. 1, 01.01.2014, p. 87-94.

Research output: Contribution to journalArticle

Leiphrakpam, Premila D. ; Agarwal, Ekta ; Mathiesen, Michelle ; Haferbier, Katie L. ; Brattain, Michael G. ; Chowdhury, Sanjib. / In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. In: Oncology reports. 2014 ; Vol. 31, No. 1. pp. 87-94.
@article{794a6a4760694262b897b3c4c64e3e85,
title = "In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer",
abstract = "The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is the second most common cause of cancer death. The study was designed to evaluate the effects of two IGF-1R antagonists, MK-0646, a recombinant fully humanized monoclonal antibody and OSI-906, a small molecule tyrosine kinase inhibitor on CRC cells. Xenograft study was performed on IGF-1R-dependent CRC cell lines for analyzing the antitumor activity of MK-0646 and OSI-906. Tumor proliferation and apoptosis were assessed using Ki67 and TUNEL assays, respectively. We also performed in vitro characterization of MK-0646 and OSI-906 treatment on CRC cells to identify mechanisms associated with drug-induced cell death. Exposure of the GEO and CBS tumor xenografts to MK-0646 or OSI-906 led to a decrease in tumor growth. TUNEL analysis showed an increase of approximately 45-55{\%} in apoptotic cells in both MK-0646 and OSI-906 treated tumor samples. We report the novel finding that treatment with IGF-1R antagonists led to downregulation of X-linked inhibitor of apoptosis (XIAP) protein involved in cell survival and inhibition of cell death. In conclusion, IGF-1R antagonists (MK-0646 and OSI-906) demonstrated single agent inhibition of subcutaneous CRC xenograft growth. This was coupled to pro-apoptotic effects resulting in downregulation of XIAP and inhibition of cell survival. We report a novel mechanism by which MK-0646 and OSI-906 elicits cell death in vivo and in vitro. Moreover, these results indicate that MK-0646 and OSI-906 may be potential anticancer candidates for the treatment of patients with IGF-1R-dependent CRC.",
keywords = "Antitumor activity, Cell survival, Colorectal cancer, IGF-1R, MK-0646, OSI-906, X-linked inhibitor of apoptosis",
author = "Leiphrakpam, {Premila D.} and Ekta Agarwal and Michelle Mathiesen and Haferbier, {Katie L.} and Brattain, {Michael G.} and Sanjib Chowdhury",
year = "2014",
month = "1",
day = "1",
doi = "10.3892/or.2013.2819",
language = "English (US)",
volume = "31",
pages = "87--94",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer

AU - Leiphrakpam, Premila D.

AU - Agarwal, Ekta

AU - Mathiesen, Michelle

AU - Haferbier, Katie L.

AU - Brattain, Michael G.

AU - Chowdhury, Sanjib

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is the second most common cause of cancer death. The study was designed to evaluate the effects of two IGF-1R antagonists, MK-0646, a recombinant fully humanized monoclonal antibody and OSI-906, a small molecule tyrosine kinase inhibitor on CRC cells. Xenograft study was performed on IGF-1R-dependent CRC cell lines for analyzing the antitumor activity of MK-0646 and OSI-906. Tumor proliferation and apoptosis were assessed using Ki67 and TUNEL assays, respectively. We also performed in vitro characterization of MK-0646 and OSI-906 treatment on CRC cells to identify mechanisms associated with drug-induced cell death. Exposure of the GEO and CBS tumor xenografts to MK-0646 or OSI-906 led to a decrease in tumor growth. TUNEL analysis showed an increase of approximately 45-55% in apoptotic cells in both MK-0646 and OSI-906 treated tumor samples. We report the novel finding that treatment with IGF-1R antagonists led to downregulation of X-linked inhibitor of apoptosis (XIAP) protein involved in cell survival and inhibition of cell death. In conclusion, IGF-1R antagonists (MK-0646 and OSI-906) demonstrated single agent inhibition of subcutaneous CRC xenograft growth. This was coupled to pro-apoptotic effects resulting in downregulation of XIAP and inhibition of cell survival. We report a novel mechanism by which MK-0646 and OSI-906 elicits cell death in vivo and in vitro. Moreover, these results indicate that MK-0646 and OSI-906 may be potential anticancer candidates for the treatment of patients with IGF-1R-dependent CRC.

AB - The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is the second most common cause of cancer death. The study was designed to evaluate the effects of two IGF-1R antagonists, MK-0646, a recombinant fully humanized monoclonal antibody and OSI-906, a small molecule tyrosine kinase inhibitor on CRC cells. Xenograft study was performed on IGF-1R-dependent CRC cell lines for analyzing the antitumor activity of MK-0646 and OSI-906. Tumor proliferation and apoptosis were assessed using Ki67 and TUNEL assays, respectively. We also performed in vitro characterization of MK-0646 and OSI-906 treatment on CRC cells to identify mechanisms associated with drug-induced cell death. Exposure of the GEO and CBS tumor xenografts to MK-0646 or OSI-906 led to a decrease in tumor growth. TUNEL analysis showed an increase of approximately 45-55% in apoptotic cells in both MK-0646 and OSI-906 treated tumor samples. We report the novel finding that treatment with IGF-1R antagonists led to downregulation of X-linked inhibitor of apoptosis (XIAP) protein involved in cell survival and inhibition of cell death. In conclusion, IGF-1R antagonists (MK-0646 and OSI-906) demonstrated single agent inhibition of subcutaneous CRC xenograft growth. This was coupled to pro-apoptotic effects resulting in downregulation of XIAP and inhibition of cell survival. We report a novel mechanism by which MK-0646 and OSI-906 elicits cell death in vivo and in vitro. Moreover, these results indicate that MK-0646 and OSI-906 may be potential anticancer candidates for the treatment of patients with IGF-1R-dependent CRC.

KW - Antitumor activity

KW - Cell survival

KW - Colorectal cancer

KW - IGF-1R

KW - MK-0646

KW - OSI-906

KW - X-linked inhibitor of apoptosis

UR - http://www.scopus.com/inward/record.url?scp=84891914719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891914719&partnerID=8YFLogxK

U2 - 10.3892/or.2013.2819

DO - 10.3892/or.2013.2819

M3 - Article

C2 - 24173770

AN - SCOPUS:84891914719

VL - 31

SP - 87

EP - 94

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -